Payment overview · 2025
General Payments
$3,286.75
128 reported records · 18 companies
Healthcare provider profile · identity verified
Shashi K Sharma, D.M.
Allopathic & Osteopathic Physicians|Internal Medicine|Cardiovascular Disease · VISALIA, CA · NPI 1356487656
Verified facts
What the public records show
CMS Open Payments records show Shashi K Sharma, D.M. received $3,286.75 in general payments during 2025 across 128 reported records.
Boston Scientific Corporation accounted for 14.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 26 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Kerendia, Tezspire, Verquvo, Vyndaqel.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TEZSPIRE as an associated drug or biological on 22824 records involving 7320 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Tezspire by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 123 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 319 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TEZSPIRE as an associated drug or biological on 33983 records involving 10291 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Tezspire by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 241 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNJARDY as an associated drug or biological on 33 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Synjardy by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VERQUVO as an associated drug or biological on 38060 records involving 12268 distinct recipient NPIs. Public Medicare Part D data also shows 145 claims for Verquvo by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 532 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 140 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 424 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VYNDAMAX as an associated drug or biological on 1880 records involving 1527 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Vyndamax by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VYNDAQEL as an associated drug or biological on 31283 records involving 13357 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Vyndaqel by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $489.04 | 14.9% | 8 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $460.50 | 14.0% | 32 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$440.74 | 13.4% | 6 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $230.74 | 7.0% | 8 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $216.83 | 6.6% | 7 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $207.98 | 6.3% | 17 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $203.01 | 6.2% | 9 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $200.17 | 6.1% | 12 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $155.04 | 4.7% | 7 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $137.69 | 4.2% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $127.65 | 3.9% | 5 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $120.37 | 3.7% | 5 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $99.11 | 3.0% | 4 | 2025 |
| Reflow Medical Inc | Unresolved — no canonical attribution shown | $61.64 | 1.9% | 2 | 2025 |
| Bard Peripheral Vascular, Inc. | Unresolved — no canonical attribution shown | $54.57 | 1.7% | 2 | 2025 |
| BridgeBio Pharma, Inc. | Unresolved — no canonical attribution shown | $39.06 | 1.2% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $22.41 | 0.7% | 1 | 2025 |
| Becton, Dickinson and Company | Unresolved — no canonical attribution shown | $20.20 | 0.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $3,084.29 | 125 |
| Travel and Lodging | $182.24 | 2 |
| Education | $20.22 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $359.09 | 23 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $203.01 | 9 | 2025 |
Source payment records
|
|||||
| SQ-RX PULSE GENERATOR Normalized: sq rx pulse generator |
Device | Boston Scientific Corporation | $175.29 | 2 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $168.95 | 9 | 2025 |
Source payment records
|
|||||
| LUX-Dx Insertable Cardiac Monitor Normalized: lux dx insertable cardiac monitor |
Device | Boston Scientific Corporation | $161.96 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $155.94 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $155.04 | 7 | 2025 |
Source payment records
|
|||||
| Coronary Other Normalized: coronary other |
Device | Philips North America LLC | $137.69 | 1 | 2025 |
Source payment records
|
|||||
| COREVALVE EVOLUT R Normalized: corevalve evolut r |
Device | Medtronic, Inc. | $133.46 | 1 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $127.65 | 5 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $125.10 | 2 | 2025 |
Source payment records
|
|||||
| AMVUTTRA Normalized: amvuttra |
Drug | Alnylam Pharmaceuticals Inc. | $120.37 | 5 | 2025 |
Source payment records
|
|||||
| MICRA Normalized: micra |
Device | Medtronic, Inc. | $111.86 | 2 | 2025 |
Source payment records
|
|||||
| myLUX Patient Kit with mobile device Normalized: mylux patient kit with mobile device |
Device | Boston Scientific Corporation | $104.10 | 2 | 2025 |
Source payment records
|
|||||
| TEZSPIRE Normalized: tezspire |
Biological | Amgen Inc. | $101.41 | 9 | 2025 |
Source payment records
|
|||||
| LOKELMA Normalized: lokelma |
Drug | AstraZeneca Pharmaceuticals LP | $100.55 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $99.11 | 4 | 2025 |
Source payment records
|
|||||
| LATITUDE Communicator Power Supply Normalized: latitude communicator power supply |
Device | Boston Scientific Corporation | $47.69 | 1 | 2025 |
Source payment records
|
|||||
| RotarexS 6 F x 135 cm Normalized: rotarexs 6 f x 135 cm |
Device | Bard Peripheral Vascular, Inc., Becton, Dickinson and Company | $47.23 | 2 | 2025 |
Source payment records
|
|||||
| Adempas Normalized: adempas |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $45.91 | 2 | 2025 |
Source payment records
|
|||||
| Attruby Normalized: attruby |
Drug | BridgeBio Pharma, Inc. | $39.06 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $39.03 | 8 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $36.34 | 2 | 2025 |
Source payment records
|
|||||
| LifeStent Solo Vascular Stent Normalized: lifestent solo vascular stent |
Device | Bard Peripheral Vascular, Inc. | $27.54 | 1 | 2025 |
Source payment records
|
|||||
| TRICLIP Normalized: triclip |
Device | Abbott Laboratories | $22.41 | 1 | 2025 |
Source payment records
|
|||||
| HAWKONE Normalized: hawkone |
Device | Medtronic, Inc. | $13.18 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 424 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 319 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 241 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 36 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TEZSPIRE tezspire |
2025 | Tezspire | 2024 | 51 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VERQUVO verquvo |
2025 | Verquvo | 2024 | 145 | exact normalized | Medicare Part D |
| VYNDAQEL vyndaqel |
2025 | Vyndaqel | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | TEZSPIRE open payments reported associated product |
CMS Open Payments — General Payments 22824 supporting records · 7320 recipient NPIs · example record 1226871881 |
Tezspire · 2024 Exact normalized brand match · 1 Part D row |
51 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
123 | 41 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
319 | 87 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | TEZSPIRE open payments reported associated product |
CMS Open Payments — General Payments 33983 supporting records · 10291 recipient NPIs · example record 1206131392 |
Tezspire · 2024 Exact normalized brand match · 1 Part D row |
51 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
241 | 65 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SYNJARDY open payments reported associated product |
CMS Open Payments — General Payments 33 supporting records · 33 recipient NPIs · example record 1222725005 |
Synjardy · 2024 Exact normalized brand match · 1 Part D row |
50 | 11 |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | VERQUVO open payments reported associated product |
CMS Open Payments — General Payments 38060 supporting records · 12268 recipient NPIs · example record 1237992208 |
Verquvo · 2024 Exact normalized brand match · 1 Part D row |
145 | 31 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
532 | 145 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
140 | 36 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
424 | 109 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | VYNDAMAX open payments reported associated product |
CMS Open Payments — General Payments 1880 supporting records · 1527 recipient NPIs · example record 1228795749 |
Vyndamax · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | VYNDAQEL open payments reported associated product |
CMS Open Payments — General Payments 31283 supporting records · 13357 recipient NPIs · example record 1228794133 |
Vyndaqel · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1346 | 420 |
| Clopidogrel | Clopidogrel Bisulfate | 908 | 270 |
| Metoprolol Succinate | Metoprolol Succinate | 713 | 205 |
| Ezetimibe | Ezetimibe | 624 | 170 |
| Repatha Sureclick | Evolocumab | 623 | 88 |
| Amlodipine Besylate | Amlodipine Besylate | 581 | 186 |
| Losartan Potassium | Losartan Potassium | 570 | 177 |
| Carvedilol | Carvedilol | 553 | 161 |
| Entresto | Sacubitril/Valsartan | 532 | 145 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 492 | 144 |
| Eliquis | Apixaban | 424 | 109 |
| Spironolactone | Spironolactone | 366 | 117 |
| Farxiga | Dapagliflozin Propanediol | 319 | 87 |
| Pantoprazole Sodium | Pantoprazole Sodium | 297 | 87 |
| Furosemide | Furosemide | 255 | 89 |
| Jardiance | Empagliflozin | 241 | 65 |
| Xarelto | Rivaroxaban | 202 | 45 |
| Amiodarone Hcl | Amiodarone Hcl | 200 | 64 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 185 | 58 |
| Levothyroxine Sodium | Levothyroxine Sodium | 168 | 47 |
| Nitroglycerin | Nitroglycerin | 168 | 95 |
| Lisinopril | Lisinopril | 167 | 50 |
| Clonidine | Clonidine | 166 | 49 |
| Ranolazine Er | Ranolazine | 164 | 44 |
| Potassium Chloride | Potassium Chloride | 162 | 46 |
| Verquvo | Vericiguat | 145 | 31 |
| Ozempic | Semaglutide | 140 | 36 |
| Gabapentin | Gabapentin | 134 | 46 |
| Hydrochlorothiazide | Hydrochlorothiazide | 132 | 49 |
| Bumetanide | Bumetanide | 131 | 39 |
| Metformin Hcl | Metformin Hcl | 131 | 50 |
| Brilinta | Ticagrelor | 123 | 41 |
| Hydralazine Hcl | Hydralazine Hcl | 108 | 29 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 107 | 32 |
| Clonidine Hcl | Clonidine Hcl | 100 | 30 |
| Digoxin | Digoxin | 92 | 21 |
| Metoprolol Tartrate | Metoprolol Tartrate | 88 | 26 |
| Torsemide | Torsemide | 85 | 25 |
| Meloxicam | Meloxicam | 83 | 25 |
| Omeprazole | Omeprazole | 83 | 28 |
| Flecainide Acetate | Flecainide Acetate | 80 | 19 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 75 | 38 |
| Pioglitazone Hcl | Pioglitazone Hcl | 74 | 23 |
| Icosapent Ethyl | Icosapent Ethyl | 69 | 13 |
| Atenolol | Atenolol | 65 | 19 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 61 | 17 |
| Metolazone | Metolazone | 60 | 17 |
| Allopurinol | Allopurinol | 57 | 20 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 57 | 12 |
| Dapagliflozin | Dapagliflozin Propanediol | 57 | 20 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 56 | 15 |
| Tamsulosin Hcl | Tamsulosin Hcl | 52 | 17 |
| Tezspire | Tezepelumab-Ekko | 51 | suppressed |
| Pregabalin | Pregabalin | 50 | 22 |
| Synjardy | Empagliflozin/Metformin Hcl | 50 | 11 |
| Nebivolol Hcl | Nebivolol Hcl | 49 | 14 |
| Midodrine Hcl | Midodrine Hcl | 47 | 13 |
| Prednisone | Prednisone | 47 | 18 |
| Warfarin Sodium | Warfarin Sodium | 47 | 11 |
| Valsartan | Valsartan | 45 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 43 | 16 |
| Buspirone Hcl | Buspirone Hcl | 39 | 11 |
| Mirtazapine | Mirtazapine | 39 | 12 |
| Labetalol Hcl | Labetalol Hcl | 38 | 11 |
| Kerendia | Finerenone | 36 | suppressed |
| Cilostazol | Cilostazol | 35 | 15 |
| Meclizine Hcl | Meclizine Hcl | 35 | 15 |
| Dexlansoprazole Dr | Dexlansoprazole | 34 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 30 | 15 |
| Eplerenone | Eplerenone | 29 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 29 | 13 |
| Nexlizet | Bempedoic Acid/Ezetimibe | 27 | suppressed |
| Nifedipine Er | Nifedipine | 27 | suppressed |
| Vascepa | Icosapent Ethyl | 27 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 25 | 11 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 24 | suppressed |
| Levofloxacin | Levofloxacin | 23 | 23 |
| Vyndamax | Tafamidis | 23 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 20 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 20 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 19 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 19 | suppressed |
| Vyndaqel | Tafamidis Meglumine | 19 | suppressed |
| Corlanor | Ivabradine Hcl | 18 | suppressed |
| Nexletol | Bempedoic Acid | 18 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 17 | suppressed |
| Januvia | Sitagliptin Phosphate | 17 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 17 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 17 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 16 | suppressed |
| Mounjaro | Tirzepatide | 16 | suppressed |
| Ramipril | Ramipril | 16 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 15 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 15 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 14 | suppressed |
| Famotidine | Famotidine | 14 | suppressed |
| Finasteride | Finasteride | 14 | suppressed |
| Levetiracetam | Levetiracetam | 14 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 14 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 14 | suppressed |
| Amoxicillin | Amoxicillin | 13 | 11 |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 13 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 13 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 13 | 11 |
| Alprazolam | Alprazolam | 12 | suppressed |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Azithromycin | Azithromycin | 12 | 12 |
| Baclofen | Baclofen | 12 | suppressed |
| Simvastatin | Simvastatin | 12 | suppressed |
| Sotalol | Sotalol Hcl | 12 | suppressed |
| Trulicity | Dulaglutide | 12 | suppressed |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 11 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 11 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 11 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $3,286.75 · 128 records | Boston Scientific Corporation | AIRSUPRA, AMVUTTRA, Adempas, Attruby, BREZTRI, COREVALVE EVOLUT R, Coronary Other, ELIQUIS, FARXIGA, HAWKONE, JARDIANCE, Kerendia, LATITUDE Communicator Power Supply, LEQVIO, LOKELMA, LUX-Dx Insertable Cardiac Monitor, LifeStent Solo Vascular Stent, MICRA, REPATHA, RotarexS 6 F x 135 cm, SQ-RX PULSE GENERATOR, TEZSPIRE, TRICLIP, VERQUVO, VYNDAQEL, myLUX Patient Kit with mobile device | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error